Harel Insurance Investments & Financial Services Ltd. lessened its holdings in shares of Mazor Robotics Ltd. (NASDAQ:MZOR) by 11.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 159,501 shares of the medical instruments supplier’s stock after selling 20,679 shares during the period. Harel Insurance Investments & Financial Services Ltd. owned about 0.62% of Mazor Robotics worth $7,875,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in MZOR. Quantbot Technologies LP bought a new stake in Mazor Robotics during the 2nd quarter valued at approximately $135,000. JPMorgan Chase & Co. boosted its position in Mazor Robotics by 398.5% during the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after acquiring an additional 5,579 shares in the last quarter. BB&T Securities LLC bought a new stake in Mazor Robotics during the 2nd quarter valued at approximately $248,000. Dimensional Fund Advisors LP boosted its position in Mazor Robotics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock valued at $296,000 after acquiring an additional 641 shares in the last quarter. Finally, ProVise Management Group LLC bought a new stake in Mazor Robotics during the 2nd quarter valued at approximately $422,000. Institutional investors own 25.53% of the company’s stock.

Shares of Mazor Robotics Ltd. (MZOR) traded up $1.08 on Tuesday, hitting $61.31. The stock had a trading volume of 740,806 shares, compared to its average volume of 664,924. Mazor Robotics Ltd. has a 12-month low of $20.19 and a 12-month high of $65.97.

Several research firms have weighed in on MZOR. Ladenburg Thalmann Financial Services set a $67.00 price objective on Mazor Robotics and gave the company a “buy” rating in a research report on Monday, October 30th. Zacks Investment Research raised Mazor Robotics from a “sell” rating to a “buy” rating and set a $41.00 price objective on the stock in a research report on Tuesday, August 15th. Barclays PLC reaffirmed a “hold” rating and set a $34.00 price objective on shares of Mazor Robotics in a research report on Wednesday, October 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research report on Wednesday, August 30th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.83.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/mazor-robotics-ltd-mzor-shares-sold-by-harel-insurance-investments-financial-services-ltd/1685543.html.

Mazor Robotics Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Institutional Ownership by Quarter for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.